News

Since 2014 when a sheet of retinal pigment epithelial cells derived from iPS cells was transplanted into patients with age-related macular degeneration, clinical trials have been conducted with various cell types derived from iPS cells.

In a study of 1.7 million older Americans by a team of researchers from the University of Toronto, those living in counties with an average temperature of 60°F or above had an increased chance of suffering serious vision impairment than those in cooler counties.

A study found the approach identifies high-risk patients so all preemies don’t need to undergo an invasive eye exam.

Surgeon discusses latest trends for treating cornea.

Trainees learn to recognize key pathologies seen in fundus examinations, OCT images

OCT methods are invaluable in the assessment of patients with the condition.

Clinical trial investigator Victor H. Gonzalez, MD, presented data at the 83rd Scientific Sessions of the American Diabetes Association in San Diego, California.

Orbis International physician spotlights the latest trends for cataract surgery training.

Procedures in the pipeline hold greater appeal for cataract and refractive surgeons, patients.

Special Superior Court Judge Mark A. Davis ruled that Michael Woodcock, MD’s failure to answer court filings did not mean he admitted his guilt in the allegations made by Cumberland County Hospital System.

According to Horizon Therapeutics, the analysis shows subclinical spinal cord lesions were associated with future NMOSD attacks. The analysis was being presented at the 9th Congress of the European Academy of Neurology in Budapest.

Results reported in JAMA Ophthalmology show that about 20% of those with diabetic retinopathy have a case that could threaten their vision.

The investigators evaluated corrective surgery procedures to determine their effect on ocular outcomes.

According to the companies, the divested assets will include Xiidra and SAF312, a potential therapy for chronic ocular surface pain. The deal is expected to close later this year.

In his role as president elect, SriniVas Sadda, MD, will continue to serve on the board as well as begin planning for his term as president, which will kick off next May at the conclusion of ARVO’s 2024 Annual Meeting in Seattle, Washington.

As part of its effort, the company is kicking off a new social media campaign in July designed to increase the understanding of dry eye disease.

William B. Trattler, MD, highlights some of the novel therapies for dry eye that have recently been approved by the FDA, along with various treatment approaches that are in development.

The company seeks to replicate European success of the ELIOS procedure in the US market.

Multidisciplinary ophthalmic genetics clinic adds efficiency to process.

According to Regeneron, visual gains and safety of aflibercept 8 mg remained consistent with the established profile of aflibercept 2 mg Injection.

An expert discusses how to ensure optimal administration.

Horizon Therapeutics announced the Brazilian Health Regulatory Agency (ANVISA) has approved TEPEZZA as the first and only medicine approved in Brazil for treatment of thyroid eye disease.

A recently completed non-human primate study of VGX-0111 demonstrated good tolerability, provided strong transgene expression in the targeted region of the retina, and increased production of the lipids whose decline is associated with macular degeneration.

Data from IG-002, Intergalactic's lead program, demonstrate persistent ABCA4 expression in non-human primate retinas over six months after a single administration, and support plan to advance IG-002 into Phase 1 trials in 2024.

Sparklers and firecrackers are at the top of the list for fireworks-related injuries. The organization is advising the public to leave fireworks to licensed operators.

Experts weigh pros and cons of treatment option for orbital cellulitis in pediatric patients

The funds will be used to further develop the company’s Calibreye System that aims to optimize reduction of intraocular pressure (IOP) for patients with moderate to advanced glaucoma.